Expertise in
1
conditions

Ta-chung Chao

No. 201, Sec. 2, Shipai Rd, 
Beitou, TPQ, TW 
Expertise in
1
conditions
No. 201, Sec. 2, Shipai Rd, 
Beitou, TPQ, TW 
OverviewLocationsClinical Research

Overview

Ta-chung Chao practices in Beitou, Taiwan. Chao is highly rated in 1 condition, according to our data. Their top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, and Acute Pain.

Their clinical research consists of co-authoring 82 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 201, Sec. 2, Shipai Rd, Beitou, TPQ 11217, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Enrollment Status: Completed
Publish Date: March 12, 2025
Intervention Type: Drug
Study Phase: Phase 1
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Enrollment Status: Terminated
Publish Date: March 03, 2022
Intervention Type: Drug
Study Drug: Oraxol
Study Phase: Phase 1
An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain
An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain
Enrollment Status: Completed
Publish Date: March 18, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

82 Total Publications

Real-world evaluation of CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: Prognostic effect of proton pump inhibitor use.
Real-world evaluation of CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: Prognostic effect of proton pump inhibitor use.
Journal: The oncologist
Published: April 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chao's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile